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Abstract
Objective: Drug resistance is a major concern in the treatment of individuals with 
 epilepsy. No genetic markers for resistance to individual antiseizure medication 
(ASM) have yet been identified. We aimed to identify the role of rare genetic variants 
in drug resistance for three common ASMs: levetiracetam (LEV), lamotrigine (LTG), 
and valproic acid (VPA).
Methods: A cohort of 1622 individuals of European descent with epilepsy was deeply 
phenotyped and underwent whole exome sequencing (WES), comprising 575 taking 
LEV, 826 LTG, and 782 VPA. We performed gene- and gene set–based collapsing 
analyses comparing responders and nonresponders to the three drugs to determine the 
burden of different categories of rare genetic variants.
Results: We observed a marginally significant enrichment of rare missense, truncat-
ing, and splice region variants in individuals who were resistant to VPA compared to 
VPA responders for genes involved in VPA pharmacokinetics. We also found a bor-
derline significant enrichment of truncating and splice region variants in the synaptic 
vesicle glycoprotein (SV2) gene family in nonresponders compared to responders to 
LEV. We did not see any significant enrichment using a gene-based approach.
Significance: In our pharmacogenetic study, we identified a slightly increased bur-
den of damaging variants in gene groups related to drug kinetics or targeting in in-
dividuals presenting with drug resistance to VPA or LEV. Such variants could thus 
determine a genetic contribution to drug resistance.
K E Y W O R D S
burden analysis, lamotrigine, levetiracetam, pharmacogenomics, rare variants, valproic acid
1 |  INTRODUCTION
Drug resistance is a major challenge in the care of people 
with epilepsy. The International League Against Epilepsy 
(ILAE) defines drug resistance as the failure of at least two 
tolerated and appropriate antiseizure medications (ASMs) 
to achieve ongoing seizure freedom.1 The odds that peo-
ple with drug-resistant epilepsy will eventually reach 
seizure freedom are marginal.2 Several new ASMs have 
been licensed in recent years, but the proportion of peo-
ple with epilepsy who are drug-resistant has not changed 
significantly.3
The response rates of the more than 20 approved ASMs 
do not seem to differ considerably, although head-to-head 
comparisons are few.4,5 The superiority of ethosuximide and 
valproic acid (VPA) compared with lamotrigine (LTG) in 
Key Point
• Pharmacogenetic markers for response to antisei-
zure medication (ASM) response could improve 
treatment quality and patient safety
• We performed burden analyses of 1622 whole 
exome sequenced individuals to determine the 
role of rare variants in resistance to specific ASMs
• Rare missense and truncating variants in genes in-
volved in valproic acid pharmacokinetics are en-
riched in individuals who are resistant to valproic acid
• Truncating variants in synaptic vesicle glycoprotein 
(SV2) family genes are enriched in individuals who 
are resistant to levetiracetam
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people with childhood absence epilepsy (CAE),6 or of VPA 
compared with LTG and topiramate in people with genetic 
generalized epilepsy (GGE)7 or juvenile myoclonic epilepsy 
(JME),8 are exceptions to this rule. Considering the reten-
tion rate of ASMs, other studies favor LTG and levetirace-
tam (LEV) because of their superior tolerability.9 In light of 
the growing evidence of the teratogenicity of VPA, its use 
in women of child-bearing age has been widely restricted.10 
Usually, clinical practitioners recommend an ASM based on 
various factors such as age, gender, comorbidities, seizure 
type, and potential drug interactions or adverse drug reactions 
(ADRs). Finding an effective and well-tolerated ASM is, how-
ever, often the result of an arduous trial-and-error process.
The aim of pharmacogenomics is to promote personalized 
medicine by means of genetic markers that allow the predic-
tion of drug response or ADRs. Whereas in other medical 
fields notable advancements have led to the incorporation of 
pharmacogenomic findings in clinical decision-making,11 
findings relevant to epilepsy therapy, so far, have fallen 
short of expectations.12 Several studies report association 
of genetic polymorphisms with cutaneous ADRs in people 
receiving treatment with aromatic ASMs13,14; however, the 
practical meaning of these findings remains controversial.15 
The evidence of genetic markers for ASM response is even 
more scant. One study that examined common variants in 
candidate genes reported the ABCB1 drug transporter as 
well as in CACNA1H and CACNA1I, subunits of T-type 
calcium channels, to be associated with response to etho-
suximide and LTG.16 In previous studies, we aimed to iden-
tify common genetic variants via genome wide association 
studies (GWAS) based on single nucleotide polymorphism 
(SNP) chip data but failed to produce significant association 
signals for response to lacosamide,17 VPA, LTG, and LEV.18
Here, based on exome sequencing data, we aimed to in-
vestigate the genetic risk of rare variants for drug response 
to three frequently used ASMs—LEV, LTG, and VPA—by 
assessing the burden of variants at the gene level as well as in 
sets of candidate genes in a large cohort.
2 |  METHODS
2.1 | Ethics statement
All study participants provided written, informed consent for 
genetic analyses. Local institutional review boards reviewed 
and approved study protocols at each contributing site.
2.2 | Study design
The epilepsy cohort was derived from the EpiPGX Consortium 
(https://www.epipgx.eu/), which was established in 2012 to 
identify genetic biomarkers of epilepsy treatment response and 
ADRs. EpiPGX is a European-wide epilepsy research partner-
ship under the European Commission Seventh Framework 
Protocol (FP7). Recruitment sites are listed in Appendix S2.
This case-control study is based on the retrospective 
evaluation of individual data. Relevant patient data were ex-
tracted from medical records by trained personnel and col-
lected in a common electronic case report form (eCRF) used 
by all consortium sites. Our cohorts consisted exclusively of 
individuals of non-Finnish European ancestry.
We included individuals that were exposed to LTG, VPA, 
or LEV. Besides carbamazepine (CBZ), these are the most 
commonly used ASMs in Europe19 and are broadly available.20 
They are approved for use in both focal epilepsy (FE) and GGE.
2.3 | Cohort description and 
phenotype definition
Individuals were selected according to our inclusion criteria 
from more than 12 000 individuals who were documented in 
the eCRF. Our cohort comprised 1622 individuals, of which 
975 were female (60%), with a median age at onset of epi-
lepsy of 15 years (±15.6). A total of 847 individuals (52%) 
had the diagnosis of FE; the remainder were diagnosed with 
GGE. Epilepsy diagnosis was based on current ILAE cri-
teria.21 The GGE group comprised individuals with JME 
(259), CAE (131), juvenile absence epilepsy (JAE, 111), 
and GGE with bilateral tonic-clonic seizures only (EGTCS, 
274). EGTCS diagnosis required the absence of other seizure 
types, electroencephalography (EEG) showing generalized 
epileptic discharges, and normal magnetic resonance imag-
ing (MRI). The FE cohort comprised individuals with struc-
tural epilepsy (259) and nonacquired focal epilepsy (NAFE, 
578). Individuals with an unknown type of epilepsy, a known 
genetic cause of epilepsy, or a classic syndrome of develop-
mental and epileptic encephalopathy (DEE) were excluded.
We based our drug response categories on the EpiPGX 
phenotype definitions: Response to a given ASM was de-
fined as seizure freedom under ongoing treatment for at least 
1 year and prior to initiation of any other treatment. ASM 
resistance was defined as recurring seizures at ≥50% of pre-
treatment seizure frequency given adequate dosage. Dosage 
requirements for the classification of drug resistance were a 
minimal daily dose of 150 mg for LTG, and 1000 mg for VPA 
and LEV, respectively. For response classification, lower 
doses were accepted on a case-by-case evaluation left to the 
discretion of the neurologist (eg, 100 mg LTG). Individuals 
with recurrent noncompliance were excluded from the anal-
ysis. Several individuals fulfilled inclusion criteria for more 
than one of the three ASM groups and were therefore in-
cluded in more than one analysis. The breakdown per ASM 
is shown in Table 1.
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2.4 | Sequencing and genotyping
Samples were sequenced at two sites: 1157 at DeCODE ge-
netics (Reykjavik, Iceland) using the Illumina Nextera target 
enrichment platform, 465 at the Genome Quebec Innovation 
Center (http://gqinn ovati oncen ter.com/index.aspx?l=e) using 
the Roche Nimblgen SeqCap EZ Exome target enrichment 
platform in the framework of the Canadian Epilepsy Network 
(CENet). Individual FASTQ files were aligned to human ge-
nome reference b37 with Burrows-Wheeler Aligner. Resultant 
binary alignment map files were then processed through the 
genome analysis toolkit (GATK) best practice pipeline to re-
move duplicate reads, align indels, and recalibrate base qual-
ity scores to generate individual genomic variant call format 
(GVCF) files.
Individual GVCF files were then jointly genotyped and 
underwent recalibration and filtering steps using GATK ver-
sion 3.8 and following the GATK best practice guidelines. 
We selected only biallelic variants with a genotyping qual-
ity >20 using GATK. We removed genomic positions with 
>2% missingness using VCFtools 22 to eliminate positions 
that were only present in one of the two sequencing sets.
2.5 | Variant selection and annotation
Annotation and filtration of variant consequences were per-
formed using Ensembl's Variant Effect Predictor (VEP)23 for 
human genome assemble GRCh37.
We defined the following variant groups:
• Ultra-rare variant 1 (URV1): missense variants, ≤1 in gno-
mAD (http://gnomad-old.broad insti tute.org)
• Ultra-rare variant 2 (URV2): missense variants, ≤3 in gno-
mAD; with the following subgroups:
a. Deleterious variants: SIFT24 predicts “deleterious,” and 
PolyPhen-225 predicts “damaging”
b. Benign variants: SIFT matches “tolerated,” and 
PolyPhen-2 matches “benign”
c. Synonymous variants
• INDELs: insertions and deletions with one of the follow-
ing consequences:
a. Inframe deletion/insertion
• Protein truncating variants (PTVs): Variants that fulfilled 
one of the following consequences:
a. Stop gain variant or frameshift variant
• PTVs and rare missense variants: variants either fulfilling 
the PTV criteria or missense variants with a minor allele 
frequency of ≤0.01 in the gnomAD database
• PTVs and splice region variants: variants either ful-
filling the PTV criteria or variants annotated as splice 
acceptor variant, splice donor variant, or splice region 
variant
• PTVs, splice region, and rare missense variants: variants 
either fulfilling the PTV criteria, splice region criteria, or 
variants with a minor allele frequency of ≤0.01 in the gno-
mAD database
2.6 | Principal component analysis (PCA)
For the PCA, we selected variants with a minor allele fre-
quency (MAF) >0.05 (using Plink 1.9). After pruning 
(--indep-pairwise 50 5 0.2), we performed PCA using the 
smartpca package from Eigensoft software.26 At first, we ob-
served a batch effect driven by the sequencing site. We then 
performed a logistic regression with the sequencing site as 
the dependent variable and the genotype as the independent 
variable in analogy to,27 to identify variants that were associ-
ated with the sequencing site and thus presumably spurious. 
By selecting a P-value threshold of 0.01, we excluded 2876 
variants and were able to eliminate the batch effect (Figures 
S1 and S2).
2.7 | Gene-based collapsing analysis for all 
coding variants
To assess whether nonresponders harbor a higher burden 
of coding variants, we performed gene-based collapsing 
analyses for the three ASM groups. After further filtering 
for missingness >2%, and Hardy-Weinberg P-value < .001 
across all samples using Plink 1.9, a total of 1622 indi-
viduals and 808  583 variants remained in the analysis. 
T A B L E  1  Sample data
  Levetiracetam Lamotrigine Valproic Acid
Responder Status
R 226 267 430
NR 349 559 352
Gender
M 233 308 327
F 342 518 455
Epilepsy Type
GGE 162 374 513
FE 413 452 269
Site
EpiPGX 330 549 639
CENet 245 277 143
Total 575 826 782
Note: Number of included individuals for the three ASM analyses grouped by 
response status, gender, epilepsy type, and sequencing site.
Abbreviations: CENet, Canadian Epilepsy Network; EpiPGX, Epilepsy 
Pharmacogenomics Consortium; F, female; FE, focal epilepsy; GGE, genetic 
generalized epilepsy; M, male; NR, nonresponders; R, responders.
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Nonresponders were defined as cases; responders were de-
fined as controls.
Kernel regression–based association tests were per-
formed using the SKAT-O function of the SKAT R package 
to determine an enrichment of variants on the gene level.28 
ANNOVAR software29 was used to annotate gene names. 
Gene names were used to designate variant sets, defining 
22 541 sets. Small sample size adjustment by SKAT-O was 
used. The first 10 principal components, gender, epilepsy 
type (GGE/FE), and the sequencing site were used as covari-
ates. Bonferroni correction was applied to P-values to correct 
for multiple testing, defining a P-value threshold for signifi-
cance of 2.3e-06.
2.8 | Gene-based collapsing analysis for 
rare variants
To evaluate the role of rare variants, we performed a gene-
based collapsing analysis using the SKAT-O function as 
described earlier for eight variant groups (INDELs; PTVs; 
PTVs and rare missense; PTVs and splice region; PTVs, 
splice region and rare missense; PTVs; URV1; URV2 dele-
terious; URV2 benign). The tests were performed separately 
for the three ASMs. The number of variants remaining after 
filtering for each test is depicted in Table S1. To determine 
whether our model was performing correctly, we ran the 
same analysis for URV2 synonymous variants as well, for 
which no biological effect would be expected.
2.9 | Gene set–based collapsing analysis for 
selected rare variants
We limited the gene set–based tests to five variant groups 
(PTVs; PTVs and rare missense; PTVs and splice region; 
PTVs; splice region and rare missense; URV2 deleteri-
ous) that were the most likely to harbor functional conse-
quences. We tested one or two gene sets per ASM (Table 
1). The target gene sets and ADME (absorption, distribu-
tion, metabolism, excretion) gene sets (Table S2) were 
compiled based on a literature research in PubMed. We 
did not find enough evidence to create an ADME set for 
LEV. For the VPA target gene set, we found no sufficient 
F I G U R E  1  Gene-based enrichment analysis for all variants. A, Quantile-quantile (QQ) plots of SKAT-O analyses of all coding variants for 
response to three antiseizure medications: levetiracetam, lamotrigine, and valproic acid. MAP-adjusted depicts the QQ plot adjusted for minimum 
achievable P-values. B, Corresponding Manhattan plots. Red line shows the threshold for significance
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evidence for the inclusion of genes coding for ion chan-
nels. However, VPA is also an inhibitor of histone dea-
cetylase (HDAC) genes of group 130 that were included in 
the target gene set.
The analysis was performed using the SKAT-O function 
for the three ASM groups separately, that is, a total of 25 
separate tests was performed. Because the gene sets were not 
entirely independent, we chose a false discovery rate (FDR) 
correction to account for multiple testing. A significant en-
richment was defined at an FDR <0.05.
3 |  RESULTS
3.1 | Gene-based enrichment analyses
We tested the burden of all coding variants using the SKAT 
function for LEV, LTG, and VPA separately (Figure 1). We 
could not identify any genes that surpassed the significance 
threshold after correction for multiple testing.
We then tested whether different variant groups showed 
a gene-based enrichment for the three ASM cohorts (for 
definition of variant groups, see above). After correction for 
multiple testing, we could not identify any significant asso-
ciations (Figure 2, S3-S5). The full results of the enrichment 
analysis are shown in Table S3.
3.2 | Gene set–based enrichment analysis
We next tested whether specific variant types showed an 
enrichment in ASM-specific sets based on ASM target and 
ASM ADME genes (Table 2).
For the VPA cohort, we found a marginally significant 
enrichment of all types of rare variants, including PTVs, 
rare missense (MAF  <0.01), and ultra-rare deleterious 
variants in ADME genes in individuals with resistance to 
VPA. We found no association for variants in the VPA tar-
get gene set.
For the LEV cohort, we observed a significant enrich-
ment of PTVs in conjunction with splice-region variants 
in the SV2 gene group in association with drug resistance. 
However, we did not observe this effect for PTVs alone, 
as only one variant in the nonresponder group remained 
F I G U R E  2  Gene-based enrichment analysis for ultra-rare deleterious missense variants (URV2). Quantile-quantile (QQ) plots of SKAT-O 
analyses of ultra-rare deleterious missense variants, that is, all variants with a frequency ≤3 in gnomAD, for response to three antiseizure 
medications: levetiracetam, lamotrigine, and valproic acid. MAP-adjusted depicts the QQ plot adjusted for minimum achievable P-values. B, 
Corresponding Manhattan plots. Red line shows the threshold for significance
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after filtering. For LTG, we did not find any significant 
association with the respective gene sets containing target 
or ADME genes.
4 |  DISCUSSION
In this exome-based pharmacogenomic study, we analyzed 
the influence of common and rare genetic variants on phar-
macoresponse for three commonly used ASMs. Although we 
did not identify an enrichment of variants in single genes, we 
found some evidence for enrichment of variants in our gene 
set–based approach. We selected our gene sets based on dif-
ferent hypotheses for the emergence of drug resistance—the 
involvement of drug transporters and other ADME genes,31,32 
and of ASM target genes.31 For VPA, we also included a set 
of HDAC genes. This set reflects the methylation hypothesis 
of drug resistance.33 Variants in HDACs could possibly alter 
the interaction with VPA and thus confer resistance to VPA 
via epigenetic mechanisms.33
We detected a marginally significant enrichment of PTVs, 
rare missense variants and splice region variants in ADME 
genes in individuals resistant to VPA. We also found some 
evidence for an enrichment of PTV in conjunction with splice 
region variants in the SV2 gene group in individuals resistant 
to LEV.
ADME genes represent a plausible mediator for ASM 
response.31,32 Our VPA-specific ADME gene set comprised 
genes of the cytochrome P450 (CYP) group,34,35 several 
UDP-glucuronosyltransferase (UGT) genes,36,37 and tran-
scriptional regulator genes of the former group.38 The asso-
ciation of the ADME gene set with pharmacoresponse was 
driven mainly by the genes UGT1A3 and UGT1A4 (Table 
S3). Both are known to catalyze the glucuronidation of VPA 
in vitro.36 Furthermore, common variants in these genes are 
correlated with the trough plasma concentration and the con-
centration to dose ratio of VPA.39 UGT1A4 has also been 
shown to be overexpressed in brain tissue of individuals with 
drug-resistant epilepsy.40 To date, however, no studies link 
these genes directly to VPA resistance.
For LEV, we found an enrichment of PTVs in conjunction 
with splice region variants in the SV2 family genes. The SV2 
family comprises the three paralogous proteins SV2A, SV2B, 
and SV2C, which are broadly expressed presynaptic proteins41 
that are involved in synaptic transmission via calcium-regulated 
exocytosis.42 SV2A has been identified as an interacting pro-
tein and the potential main binding site of LEV in the brain.43 
Although LEV does not seem to bind to SV2B directly,43 the 
latter seems to retain an important role for LEV function, none-
theless.44 LEV appears to mediate SV2A-associated decrease 
of neurotransmitter release only in synapses that do not express 
SV2B.44 The role of SV2C remains obscure given its expression 
pattern that differs from that of SV2A and SV2B,45 and there 
is no evidence for involvement in LEV pharmacodynamics. 
Therefore, only SV2A and SV2B were included in this gene set.
Unlike the ADME set, the SV2 set is based on the drug 
target hypothesis of pharmacoresistance,31 which postu-
lates that variation in ASM target proteins contributes to 
drug resistance. Previous candidate gene-based studies did 
not identify an association of common genetic variants 
in the SV2 family with epilepsy46 or LEV response,47 but 
they did not cover rare truncating or splice region variants. 
Dibbens et al48 reported no effect of genetic variants on 
LEV response in 158 individuals with epilepsy who under-
went sequencing of SV2A, but the study did not cover the 
entire SV2B and included fewer individuals. The inclusion 
criteria for drug response were also less strict than in our 
study, admitting individuals as responders that had >75% 
T A B L E  2  Results of gene set analyses
Gene sets 
(n of genes) PTV PTV/splice region PTV/rare missense
PTV/rare missense/
splice region
Ultra-rare 
deleterious missense
Levetiracetam
SV2 group (2) 1 (1) 0.04 (9.5E-03) 0.82 (6.5E-01) 0.05 (5.1E-02) 0.34 (2.0E-01)
Lamotrigine
ADME genes (6) 0.79 (2.5E-01) 0.79 (4.0E-01) 0.79 (4,9E-01) 0.79 (4.2E-01) 0.79 (4.1E-01)
Target genes (17) 0.79 (7.5E-01) 0.79 (5.9E-01) 0.79 (7.1E-01) 0.79 (7.8E-01) 0.47 (4.6E-02)
Valproic Acid
ADME genes (12) 0.03 (1.3E-02) 0.07 (3.8E-02) 0.03 (1.4E-02) 0.02 (3.5E-03) 0.02 (3.9E-03)
Target genes (4) 0.70 (6.2E-01) 0.93 (9.3E-01) 0.65 (4.3E-01) 0.70 (6.1E-01) -
Note: Results of gene set–based SKAT-O analysis based on one gene set for LEV and two gene sets LTG and VPA for five variant annotation groups. The table shows 
the FDR-adjusted P-values and the raw P-values in parentheses. After correction for multiple testing the SV2 group showed a marginally significant association with 
LEV resistance for PTV and splice region variants; VPA-specific ADME genes showed a marginally significant association for all variant groups but splice region 
variants. We found no variant fulfilling the ultra-rare deleterious missense criteria in the VPA target gene set.
Significant findings are depicted in bold.
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seizure reduction, whereas people with <75% were defined 
as nonresponders. A third group with an increase in seizure 
rate of >50% was defined as exacerbators but was a small 
group (n = 16). The less strict separation between respond-
ers and nonresponders may have obliterated any genetic 
differences. We applied stricter response definitions, ac-
knowledging the trade-off of a smaller sample size.
The association between SV2 variants and LEV resistance 
was only observable for PTVs in conjunction with splice re-
gion variants, indicating that the observed effect was mainly 
driven by splice region variants. The impact of splice region 
variants on gene expression is poorly understood. Therefore, 
our results for this gene group should be considered with 
caution and warrant evaluation in future studies.
Our study was limited by the lack of a replication co-
hort and a still relatively small sample size in the analyzed 
subgroups. Despite this, our results generate hypotheses 
for future studies that are required to confirm our findings. 
Obstacles for future larger studies are no longer the costs of 
sequencing but rather the costs and availability of manpower 
needed to collect and deeply phenotype a sufficiently large 
cohort of individuals.
In conclusion, our study sheds some light on the ques-
tion of a genetic contribution to drug resistance in epilepsy 
treatment. In the light of our and previous studies, it can be 
concluded that single variants/genes of a large effect size 
are unlikely to drive drug resistance to LEV, LTG, or VPA. 
It seems more likely that the genetic basis of drug resistance 
is heterogeneous and, as our study implies, influenced by 
rare variants affecting pharmacokinetics and pharmacody-
namics. Because many individuals with epilepsy do not re-
spond to any ASM, regardless of its mechanism of action, 
it seems obvious that other factors are involved. Thus, phar-
macoresistance may also be due to altered gene expression 
of target or ADME genes via epigenetic mechanisms such 
as DNA methylation,33 seizure-induced alterations of neural 
networks,49 or intrinsic factors mediating disease severity.50
ACKNOWLEDGMENTS
The EpiPGX Consortium was funded by FP7 grant 279062 
“EpiPGX” from the European Commission. CENet was 
funded by joint funding from Genome Canada and Genome 
Quebec. SW received funding from the German Research 
Foundation (DFG) (WO 2385/1-1), and the Clinician 
Scientist program of the University of Tübingen (418-0-
0). SaW was supported by the BOF-University of Antwerp 
(FFB180053) and FWO (1861419N). This study was 
supported in part by the Robert Bosch Stiftung Stuttgart, 
Germany, and in part by the Horizon 2020-PHC-2015 grant 
U-PGx 668353. Recruitment of patients in Tübingen was 
partly funded by the German Society for Epileptology 
(DGfE), by UCB Pharma, and by the foundation “no epi-
lep” (to HL and YGW). SLG is funded by the Canadian 
Institutes of Health Research. Part of this work was under-
taken at University College London Hospitals, which re-
ceived a proportion of funding from the NIHR Biomedical 
Research Centres funding scheme. We are grateful to 
Epilepsy Society, UK, for their support of this work. JWS is 
based at UCLH/UCL Biomedical Research Centre, which 
receives a proportion of funding from the UK Department 
of Health's NIHR Research Centres funding scheme. He re-
ceives support from the Dr Marvin Weil Epilepsy Research 
Fund and UK Epilepsy Society.
The computational analysis was performed on the 
high-performance computer system of the University of 
Luxembourg (https://hpc.uni.lu). CENet sequences were 
stored and processed on Compute Canada cluster Beluga.
CONFLICTS OF INTEREST
SW received speaker's fees and travel grants from Eisai and 
Desitin, and has served as a paid consultant to Novartis and 
Eisai. JWS has received research funding from Eisai and 
UCB, and research support and personal fees from UCB, 
GW, and Zogenix outside the submitted work. CD received 
research support for investigator-initiated studies paid to 
the institution and travel and speaker's honoraria from UCB 
Pharma. AA is employed by UCB Pharma SPRL, Belgium 
as Director. HL received honoraria for speaking or consult-
ing or travel support from Arvelle, Bial, BioMarin, Desitin, 
Eisai, and UCB, and an aforementioned unrestricted grant for 
patient recruitment from UCB. The remaining authors have 
no conflicts of interest. We confirm that we have read the 
Journal's position on issues involved in ethical publication 
and affirm that this report is consistent with those guidelines. 
We thank the patients and their families for participation in 
this research.
ORCID
Stefan Wolking   https://orcid.org/0000-0002-1460-6623 
Anne T. Nies   https://orcid.org/0000-0001-6862-0730 
Mark McCormack   https://orcid.
org/0000-0002-8213-6141 
Martin Krenn   https://orcid.org/0000-0003-3026-3082 
Rikke S. Møller   https://orcid.org/0000-0002-9664-1448 
Gianpiero L. Cavalleri   https://orcid.
org/0000-0002-9802-0506 
Norman Delanty   https://orcid.org/0000-0002-3953-9842 
Chantal Depondt   https://orcid.org/0000-0002-8452-5319 
Pasquale Striano   https://orcid.org/0000-0002-6065-1476 
Roland Krause   https://orcid.org/0000-0001-9938-7126 
Sanjay M. Sisodiya   https://orcid.
org/0000-0002-1511-5893 
REFERENCES
 1. Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, 
Mathern G, et al. Definition of drug resistant epilepsy: consensus 
   | 9WOLKING et aL
proposal by the ad hoc Task Force of the ILAE Commission on 
Therapeutic Strategies. Epilepsia. 2010;51(6):1069–77.
 2. Brodie MJ, Barry SJE, Bamagous GA, Norrie JD, Kwan P. Patterns 
of treatment response in newly diagnosed epilepsy. Neurology. 
2012;78(20):1548–54.
 3. Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in 
patients with newly diagnosed epilepsy treated with established 
and new antiepileptic drugs: a 30-year longitudinal cohort study. 
JAMA Neurol. 2018;75(3):279–86.
 4. Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy 
of modern antiepileptic drugs for refractory epilepsy: systematic 
review and meta-analysis. Epilepsia. 2010;51(1):7–26.
 5. Androsova G, Krause R, Borghei M, Wassenaar M, Auce P, 
Avbersek A, et al. Comparative effectiveness of antiepileptic drugs 
in patients with mesial temporal lobe epilepsy with hippocampal 
sclerosis. Epilepsia. 2017;58(10):1734–41.
 6. Glauser TA, Cnaan A, Shinnar S, Hirtz DG, Dlugos D, Masur D, 
et al. Ethosuximide, valproic acid, and lamotrigine in childhood 
absence epilepsy: initial monotherapy outcomes at 12 months. 
Epilepsia. 2013;54(1):141–55.
 7. Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, 
Chadwick DW, et al. The SANAD study of effectiveness of val-
proate, lamotrigine, or topiramate for generalised and unclassifi-
able epilepsy: an unblinded randomised controlled trial. Lancet. 
2007;369(9566):1016–26.
 8. Silvennoinen K, Lange N, Zagaglia S, Balestrini S, Androsova 
G, Wassenaar M, et al. Comparative effectiveness of antiepi-
leptic drugs in juvenile myoclonic epilepsy. Epilepsia Open. 
2019;4(3):420–30.
 9. Arif H, Buchsbaum R, Pierro J, Whalen M, Sims J, Resor SR, et al. 
Comparative effectiveness of 10 antiepileptic drugs in older adults 
with epilepsy. Arch Neurol. 2010;67(4):408–15.
 10. EMA. New measures to avoid valproate exposure in pregnancy 
endorsed [Internet]. EMA; 2018. Available from: https://www.
ema.europa.eu/en/docum ents/refer ral/valpr oate-artic le-31-refer 
ral-new-measu res-avoid-valpr oate-expos ure-pregn ancy-endor sed_
en-0.pdf.
 11. Daly AK. Pharmacogenetics: a general review on progress to date. 
Br Med Bull. 2017;1–15.
 12. Balestrini S, Sisodiya SM. Pharmacogenomics in epilepsy. 
Neurosci Lett. 2018;667:27–39.
 13. Chung W-H, Hung S-I, Hong H-S, Hsih M-S, Yang L-C, Ho H-C, 
et al. Medical genetics: a marker for Stevens-Johnson syndrome. 
Nature. 2004;428(6982):486.
 14. McCormack M, Gui H, Ingason A, Speed D, Wright GEB, Zhang 
EJ, et al. Genetic variation in CFH predicts phenytoin-induced mac-
ulopapular exanthema in European-descent patients. Neurology. 
2018;90(4):e332–e341.
 15. Chen Z, Liew D, Kwan P. Effects of a HLA-B*15:02 screening pol-
icy on antiepileptic drug use and severe skin reactions. Neurology. 
2014;83(22):2077–84.
 16. Glauser TA, Holland K, O’Brien VP, Keddache M, Martin 
LJ, Clark PO, et al. Pharmacogenetics of antiepileptic drug 
efficacy in childhood absence epilepsy. Ann Neurol. 2017;81(3): 
444–53.
 17. Heavin SB, McCormack M, Wolking S, Slattery L, Walley 
N, Avbersek A, et al. Genomic and clinical predictors of la-
cosamide response in refractory epilepsies. Epilepsia Open. 
2019;4(4):563–71.
 18. Wolking S, Schulz H, Nies AT, McCormack M, Schaeffeler E, 
Auce P, et al. Pharmacoresponse in genetic generalized epilepsy: a 
genome wide association study. Pharmacogenomics. In press.
 19. Hamer HM, Dodel R, Strzelczyk A, Balzer-Geldsetzer M, Reese J-
P, Schöffski O, et al. Prevalence, utilization, and costs of antiepilep-
tic drugs for epilepsy in Germany–a nationwide population-based 
study in children and adults. J Neurol. 2012;259(11):2376–84.
 20. Baftiu A, Johannessen Landmark C, Nikaj V, Neslein I-L, 
Johannessen SI, Perucca E. Availability of antiepileptic drugs 
across Europe. Epilepsia. 2015;56(12):e191–e197.
 21. Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, 
Guilhoto L, et al. ILAE classification of the epilepsies: position 
paper of the ILAE Commission for Classification and Terminology. 
Epilepsia. 2017;58(4):512–21.
 22. Danecek P, Auton A, Abecasis G, Albers CA, Banks E, DePristo 
MA, et al. The variant call format and VCFtools. Bioinformatics. 
2011;27(15):2156–8.
 23. McLaren W, Gil L, Hunt SE, Riat HS, Ritchie GRS, Thormann 
A, et al. The ensembl variant effect predictor. Genome Biol. 
2016;17(1):122.
 24. Kumar P, Henikoff S, Ng PC. Predicting the effects of coding 
non-synonymous variants on protein function using the SIFT algo-
rithm. Nat Protoc. 2009;4(7):1073–81.
 25. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova 
A, Bork P, et al. A method and server for predicting damaging mis-
sense mutations. Nat Methods. 2010;7(4):248–9.
 26. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, 
Reich D. Principal components analysis corrects for stratification 
in genome-wide association studies. Nat Genet. 2006;38(8):904–9.
 27. Anderson-Trocmé L, Farouni R, Bourgey M, Kamatani Y, Higasa 
K, Seo J-S, et al. Legacy data confound genomics studies. Wilson 
M, editor. Mol Biol Evol. 2020;37(1):2–10.
 28. Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, 
Nickerson DA, et al. Optimal unified approach for rare-variant 
association testing with application to small-sample case-con-
trol whole-exome sequencing studies. Am J Hum Genet. 
2012;91(2):224–37.
 29. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation 
of genetic variants from high-throughput sequencing data. Nucleic 
Acids Res. 2010;38(16):e164–e164.
 30. Gottlicher M. Valproic acid defines a novel class of HDAC in-
hibitors inducing differentiation of transformed cells. The EMBO 
Journal. 2001;20(24):6969–78.
 31. Löscher W. How to explain multidrug resistance in epilepsy? 
Epilepsy Curr. 2005;5(3):107–12.
 32. Weber YG, Nies AT, Schwab M, Lerche H. Genetic biomarkers in 
epilepsy. Neurotherapeutics. 2014;11(2):324–33.
 33. Kobow K, El-Osta A, Blümcke I. The methylation hypothesis 
of pharmacoresistance in epilepsy. Epilepsia. 2013;54(Suppl 
2):41–7.
 34. Kiang TKL, Ho PC, Anari MR, Tong V, Abbott FS, Chang TKH. 
Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic 
acid metabolism in hepatic microsomes from individuals with the 
CYP2C9*1/*1 genotype. Toxicol Sci. 2006;94(2):261–71.
 35. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug me-
tabolism: regulation of gene expression, enzyme activities, and im-
pact of genetic variation. Pharmacol Ther. 2013;138(1):103–41.
 36. Argikar UA, Remmel RP. Effect of aging on glucuronida-
tion of valproic acid in human liver microsomes and the role of 
10 |   WOLKING et aL
UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. 
Drug Metab Dispos. 2009;37(1):229–36.
 37. Ebner T, Burchell B. Substrate specificities of two stably expressed 
human liver UDP-glucuronosyltransferases of the UGT1 gene fam-
ily. Drug Metab Dispos. 1993;21(1):50–5.
 38. Cerveny L, Svecova L, Anzenbacherova E, Vrzal R, Staud F, Dvorak 
Z, et al. Valproic acid induces CYP3A4 and MDR1 gene expres-
sion by activation of constitutive androstane receptor and pregnane 
X receptor pathways. Drug Metab Dispos. 2007;35(7):1032–41.
 39. Chu X-M, Zhang L-F, Wang G-J, Zhang S-N, Zhou J-H, Hao H-
P. Influence of UDP-glucuronosyltransferase polymorphisms on 
valproic acid pharmacokinetics in Chinese epilepsy patients. Eur J 
Clin Pharmacol. 2012;68(10):1395–401.
 40. Ghosh C, Hossain M, Puvenna V, Martinez-Gonzalez J, 
Alexopolous A, Janigro D, et al. Expression and functional rele-
vance of UGT1A4 in a cohort of human drug-resistant epileptic 
brains. Epilepsia. 2013;54(9):1562–70.
 41. Janz R, Goda Y, Geppert M, Missler M, Südhof TC. SV2A and 
SV2B function as redundant Ca2+ regulators in neurotransmitter 
release. Neuron. 1999;24(4):1003–16.
 42. Crowder KM, Gunther JM, Jones TA, Hale BD, Zhang HZ, 
Peterson MR, et al. Abnormal neurotransmission in mice lacking 
synaptic vesicle protein 2A (SV2A). Proc Natl Acad Sci USA. 
1999;96(26):15268–73.
 43. Lynch BA, Lambeng N, Nocka K, Kensel-Hammes P, Bajjalieh 
SM, Matagne A, et al. The synaptic vesicle protein SV2A is the 
binding site for the antiepileptic drug levetiracetam. Proc Natl 
Acad Sci USA. 2004;101(26):9861–6.
 44. Ciruelas K, Marcotulli D, Sullivan JM, Bajjalieh SM. Levetiracetam 
inhibits SV2A-synaptotagmin interaction at synapses that lack 
SV2B. bioRxiv [Internet]. 2019. Available from: http://biorxiv.org/
lookup/doi/10.1101/640185.
 45. Bartholome O, VandenAckerveken P, Sánchez Gil J, de la 
Brassinne Bonardeaux O, Leprince P, Franzen R, et al. Puzzling out 
synaptic vesicle 2 family members functions. Front Mol Neurosci. 
2017;10:148.
 46. Cavalleri GL, Weale ME, Shianna KV, Singh R, Lynch JM, 
Grinton B, et al. Multicentre search for genetic susceptibility loci 
in sporadic epilepsy syndrome and seizure types: a case-control 
study. Lancet Neurol. 2007;6(11):970–80.
 47. Lynch JM, Tate SK, Kinirons P, Weale ME, Cavalleri GL, 
Depondt C, et al. No major role of common SV2A variation for 
predisposition or levetiracetam response in epilepsy. Epilepsy Res. 
2009;83(1):44–51.
 48. Dibbens LM, Hodgson BL, Helbig KL, Oliver KL, Mulley JC, 
Berkovic SF, et al. Rare protein sequence variation in SV2A 
gene does not affect response to levetiracetam. Epilepsy Res. 
2012;101(3):277–9.
 49. Fang M, Xi Z-Q, Wu Y, Wang X-F. A new hypothesis of drug re-
fractory epilepsy: neural network hypothesis. Med Hypotheses. 
2011;76(6):871–6.
 50. Rogawski MA. The intrinsic severity hypothesis of pharmacoresis-
tance to antiepileptic drugs. Epilepsia. 2013;54:33–40.
SUPPORTING INFORMATION
Additional supporting information may be found online in 
the Supporting Information section.
How to cite this article: Wolking S, Moreau C, Nies 
AT, et al; EpiPGX Consortium. Testing association of 
rare genetic variants with resistance to three common 
antiseizure medications. Epilepsia. 2020;00:1–10. 
https://doi.org/10.1111/epi.16467
